Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- “We Should Increase Our Efforts” to Promote Pharmaceutical Industry: New Health Policy Bureau Chief Takeda
August 3, 2017
- MHLW Advisory Panel Recommends Approval for Zetia/Lipitor Combo
August 3, 2017
- Bayer’s ADR Reporting Delay “Very Regrettable”: Shiozaki
August 2, 2017
- Will “Emphasize Exchange of Views” to Tackle Challenges: Pharma Bureau Chief Miyamoto
August 1, 2017
- MHLW to Support Healthcare-Related Startups from “Long-Term Perspective”: Health Minister Shiozaki
August 1, 2017
- Drug Pricing Overhaul Must Strike Balance between Benefits and Costs: Health Insurance Bureau Chief
July 31, 2017
- Govt to Discuss Platforms to Promote Expansion of Drug Makers into Emerging Markets
July 31, 2017
- MHLW Advisory Panel Backs Approval of Pfizer’s Palbociclib
July 28, 2017
- MHLW Council Recommends Switching of 4 APIs; Switching of Levonorgestrel for Emergency Contraception Disapproved
July 28, 2017
- Chuikyo Scrutiny Continues for Cost Calculation Pricing Formula
July 27, 2017
- Chuikyo Members at Odds over How to Proceed with “CEA” Debate
July 27, 2017
- Govt OKs Basic Policy for FY2018 Budget Requests
July 21, 2017
- Panel OKs 42.12 Million Yen Price Tag for Drug Makers’ MID-NET Use in PMS
July 20, 2017
- MHLW Panel to Discuss Zetia + Lipitor Combination Product on Aug. 1
July 20, 2017
- Shiozaki Says MHLW to Uphold 3-Year 1.5 Trillion Yen Cap in Social Security Cost Rise, CEFP Panelists Call for Further Curtailment
July 19, 2017
- Azithromycin under PMDA Risk Review for Acute Generalized Exanthematous Pustulosis
July 19, 2017
- MHLW to Take Strict Action on Bayer after Xarelto Survey Probe
July 19, 2017
- MHLW Panel Agrees to Compile Guidelines to Address Polypharmacy in the Elderly
July 18, 2017
- Gov’t Establishing System to Quickly Provide Unapproved Drugs to Developing Countries, Learning from Inadequate Response to Request for Avigan
July 18, 2017
- Pfizer’s Breast Cancer Med Palbociclib Up for MHLW Panel Review on July 27
July 14, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…